Aptose Biosciences Inc. (APTO) Receives $8.00 Consensus Target Price from Brokerages
Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) has received a consensus rating of “Buy” from the six brokerages that are currently covering the stock. Six equities research analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokerages that have covered the stock in the last year is $8.00.
Several research analysts recently issued reports on the company. Zacks Investment Research raised Aptose Biosciences from a “hold” rating to a “buy” rating and set a $1.00 target price on the stock in a research report on Thursday, November 17th. RBC Capital Markets reaffirmed an “outperform” rating on shares of Aptose Biosciences in a research report on Tuesday, September 13th. Royal Bank Of Canada cut their target price on Aptose Biosciences from $18.00 to $12.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 16th. Canaccord Genuity reaffirmed a “buy” rating and set a $7.00 target price on shares of Aptose Biosciences in a research report on Saturday, October 15th. Finally, Roth Capital reaffirmed a “buy” rating and set a $8.00 target price on shares of Aptose Biosciences in a research report on Friday, October 14th.
Aptose Biosciences (NASDAQ:APTO) opened at 0.9671 on Wednesday. The firm’s market capitalization is $13.01 million. The firm has a 50-day moving average price of $1.44 and a 200-day moving average price of $2.19. Aptose Biosciences has a one year low of $0.83 and a one year high of $4.33.
An institutional investor recently bought a new position in Aptose Biosciences stock. Baker BROS. Advisors LP purchased a new position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 404,211 shares of the company’s stock, valued at approximately $909,000. Baker BROS. Advisors LP owned approximately 3.14% of Aptose Biosciences at the end of the most recent quarter. 19.20% of the stock is currently owned by hedge funds and other institutional investors.
Aptose Biosciences Company Profile
Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.
Receive News & Stock Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related stocks with our FREE daily email newsletter.